Chloroquine and Hydroxychloroquine in Treatment of COVID-19 Disease | Zendy

Fatma Yıldırım | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Chloroquine and Hydroxychloroquine in Treatment of COVID-19 Disease

Author(s) -

Fatma Yıldırım

Publication year - 2020

Publication title -

journal of critical and intensive care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.104

H-Index - 5

ISSN - 2717-6428

DOI - 10.37678/dcybd.2020.2387

Subject(s) - hydroxychloroquine , chloroquine , covid-19 , pandemic , medicine , intensive care medicine , disease , virology , immunology , malaria , infectious disease (medical specialty) , outbreak

The use of chloroquine and its derivatives as an anti-viral agent is supported by pre-clinical in-vitro studies and its clinical safety is known in the term of its other indications. But there is insufficient clinical data to support its use in critically ill patients with The noval corona virus disease 2019 (COVID-19). Nevertheless, it is recommended that these drugs, which are supported by the urgency of the COVID-19 pandemic in many national guidelines and consensus reports, including our country, should be applied in accordance with the guidelines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research